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If, as is likely the
case, the exporta-
tion of clinical in-
vestigation is re-
lated to both the
advantages of over-
seas sites and issues
with the research
enterprise in the
U.S., steps should
be taken at both
venues to ensure
the optimal condi-
tions for clinical
trials everywhere.e recently held an international conference on cardiovascular translational
research and cell therapy at the University of California, San Diego. As I sat
through the presentations of very novel therapies I was struck by the fre-
uency with which the initial clinical trials were being performed outside of the U.S. In
act, I was somewhat stunned, not only that nearly every initial trial was being per-
ormed overseas, but also by the “matter of fact” manner with which this was stated. As
nvestigators and industrial representatives discussed stem cell preparations and percuta-
eous valve devices, they identified the non-U.S. sites of early studies as if this was stan-
ard procedure and to be expected. It stimulated me to give some thought to this issue
nd to discuss it with some of the individuals involved, including Food and Drug Ad-
inistration (FDA) representatives.
The increasing role of the international medical community in large-scale, multicenter
linical trials has been recognized and critiqued for several years (1). Over the past de-
ade, dramatic growth has occurred in the number of non-U.S. FDA-regulated investi-
ators, many coming from less industrialized and less wealthy nations. Although the
otential scientific and social benefits of the interaction of the worldwide medical com-
unity have been acknowledged, several concerns have arisen as well. While the increas-
ng participation of overseas physicians and institutions in multicenter clinical trials
aises a number of issues, the exportation of initial phase clinical investigation of very
ovel and hitherto untested biologicals and devices adds additional considerations. Such
nitial studies are often single centered, and sometimes lead to approval for clinical use
n other countries prior to the U.S. They clearly raise a question as to whether we in
merica are exploiting the rest of the world to prematurely test potentially hazardous
herapies, or conversely, whether our regulatory and financial environment is stifling ac-
ess to important new innovations for patients and investigators.
Conducting a clinical investigation of any type outside of the sponsor’s country im-
oses a number of disadvantages. There are obvious logistical problems such as language
ifferences and the necessity of shipping supplies and personnel to a distant location.
onitoring of such sites is often more difficult, particularly in less wealthy countries.
he apparatus needed for clinical research may be less developed and the investigators
ess experienced. The nature of the patients enrolled may differ significantly from those
n the U.S. and other countries likely to use the agents. The disease etiologies may differ
e.g., ischemic vs. nonischemic heart failure), the underlying optimal care may differ, and
ignificant genetic or genomic conditions may be present. All of these issues present
ossible obstacles to acceptance by the FDA of data generated overseas.
The foregoing difficulties may be offset by the large number of advantages to perform-
ng clinical research in other countries. The cost of conducting studies is less in most
ther countries, and much less in the developing world. The ability to rapidly acquire
atients is a major advantage for exported studies. In most of the rest of the world, re-
ionalization of health care facilities concentrates patients, and the lesser prevalence of
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Editor’s Page May 19, 2009:1919–20rivate practice may facilitate referral of patients for clini-
al trials. Enrollment in trials often provides patients with
ccess to care that would not otherwise be available, and
he financial incentives inherent in participating in re-
earch are usually greater for both patients and investiga-
ors. There is a sense that institutional review boards are
sually less stringent, the process of informed consent is
ometimes less vigorous, and the authority figure of the
hysician is a bit more prominent outside than inside of
he U.S. It is not surprising, therefore, that sponsors are
ften attracted to overseas sites for placement of studies.
owever, it should also be recognized that these factors
ould contribute to obtaining less robust data, and raise
thical concerns with the research as well.
Discussions with those involved in cutting edge innova-
ions such as stem cells and percutaneous valve devices
eveal additional factors that make exportation of clinical
esearch attractive. The European equivalent of FDA ap-
roval, the CE mark, has a high degree of credibility.
evertheless, there is an almost universal feeling that the
egulatory bar for approval of new therapies is set higher
n the U.S. even as compared with Western Europe. This
s particularly true for devices in terms of standards for
urability and fatigue, biocompatibility, Good Manufac-
uring Processes, and packaging and sterility. Indemnifica-
ion issues are also more stringent. As opposed to an ad-
isory board meeting for the FDA, the written submission
or a CE mark may be sent to only 2 or 3 reviewers. Ac-
ordingly, the pathway to achieve a CE mark seems less
nerous, and may be possible with fewer patients in a
ingle-arm study. Moreover, relatively prompt achieve-
ent of a CE mark may be of critical value to a startup
ompany by providing funds flow as well as representing
n important accomplishment upon which to base the
aising of additional capital. Given these extraordinary
dvantages of exporting early-phase clinical investigation,
ne can only wonder if much of this research will ever
eturn to the U.S.
If you are a clinical investigator in the U.S., the loss of
he opportunity to participate in early-stage clinical inves-
igation can only be viewed as a negative. Several ques-
ions regarding the exportation of research come to mind.
re we exploiting the populace of less wealthy or vigilant
ations by exposing them to research with products that
ave not been adequately evaluated for safety and thatill predominantly be used in wealthy countries like our
wn? The recent emergence of several “first in man” trials
rom sites not previously recognized for major clinical
esearch raises such a possibility. The FDA can point to
herapies such as transmyocardial laser revascularization
hat were initially approved overseas and subsequently
ound to be ineffective in larger clinical trials. Conversely,
re we in the U.S. confronted with unnecessary barriers to
linical investigation that render us not competitive to
erve as trial sites and that deprive our patients of prompt
ccess to beneficial therapies? Do FDA standards have to
e so stringent; do university costs and overhead have to
e so high; and can’t all patients who are candidates for
linical trials be centralized? If exploitation exists, this
learly raises important ethical issues that should be ad-
ressed immediately. If barriers are too great, then steps
hould be taken to remove or lessen them. If, as is likely
he case, the exportation of clinical investigation is related
o both the advantages of overseas sites and issues with
he research enterprise in the U.S., steps should be taken
t both venues to ensure the optimal conditions for clini-
al trials everywhere.
The exportation of clinical trials from the U.S. and
lsewhere in the industrialized world has many positive
spects. Participation in clinical research provides intellec-
ual involvement for physicians, potential benefits to pa-
ients, and the opportunity for industry to evaluate prod-
cts in multiple populations and clinical settings. However,
t is important that the exportation of clinical trials not be
he result of inappropriate or unacceptable conditions ei-
her in the U.S. or abroad. Ultimately, clinical trials are
eant to provide all physicians with therapies by which to
enefit all patients. They should be conducted at the best
ites by the best qualified investigators to achieve this goal.
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